Cas no 60925-61-3 (Ceforanide)

Ceforanide is a second-generation cephalosporin antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. Its chemical structure includes a beta-lactam ring, conferring bactericidal properties by inhibiting bacterial cell wall synthesis. Ceforanide exhibits enhanced stability against beta-lactamases compared to earlier cephalosporins, improving its efficacy against resistant strains. It is particularly effective against pathogens such as Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae. The compound demonstrates favorable pharmacokinetics, including prolonged serum half-life, allowing for less frequent dosing. Its clinical applications include treating respiratory, urinary tract, and soft tissue infections. Ceforanide's balanced spectrum and stability make it a reliable option for targeted antimicrobial therapy.
Ceforanide structure
Ceforanide structure
Product Name:Ceforanide
CAS No:60925-61-3
MF:C20H21N7O6S2
MW:519.554040670395
CID:57613
PubChem ID:43507
Update Time:2025-06-29

Ceforanide Chemical and Physical Properties

Names and Identifiers

    • Ceforanide
    • (6R,7R)-7-[[2-[2-(Aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    • Cefonicid Sodium
    • CEFORANIDE,JP14
    • (6R)-7t-[2-(2-aminomethyl-phenyl)-acetylamino]-3-(1-carboxymethyl-1H-tetrazol-5-ylsulfanylmethyl)-8-oxo-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    • bl s786
    • Ceforanido
    • Ceforanido [INN-Spanish]
    • Ceforanidum
    • Ceforanidum [INN-Latin]
    • Precef
    • Radacef
    • Prestwick3_000470
    • CEFORANIDE [WHO-DD]
    • CEFORANIDE (USP IMPURITY)
    • CEFORANIDE (MART.)
    • CEFORANIDE(200MG)
    • SPBio_002519
    • Ceforanide (USAN:USP:INN:BAN)
    • CEFORANIDE [MART.]
    • NCGC00179514-05
    • NSC 760049
    • BL-S786
    • 7-(o-(Aminomethyl)phenylacetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid
    • CEFORANIDE [USAN]
    • Prestwick2_000470
    • Ceforanidum (INN-Latin)
    • CEFORANIDE [INN]
    • (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    • SR-01000872614-3
    • CHEMBL1201046
    • UNII-8M1YF8951V
    • 7beta-[2-(aminomethyl)phenyl]acetamido-3-{[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl-3,4-didehydrocepham-4-carboxylic acid
    • C06884
    • NSC-760049
    • D00259
    • AKOS027427040
    • S5081
    • CCG-220470
    • (6R,7R)-7-{2-[2-(aminomethyl)phenyl]acetamido}-3-({[1-(carboxymethyl)-1H-1,2,3,4-tetrazol-5-yl]sulfanyl}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    • BSPBio_000580
    • CEFORANIDE [USP IMPURITY]
    • 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-(aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, (6R-trans)-
    • Ceforanide (USP/INN)
    • SCHEMBL122072
    • CEFORANIDE (USP-RS)
    • CEFORANIDE [ORANGE BOOK]
    • DTXSID1022760
    • BL-S 786
    • cefaronide
    • CS-0013066
    • NS00011575
    • SR-01000872614-2
    • HMS3713M22
    • Tox21_110670
    • CHEBI:3495
    • (6R,7R)-7-[2-(alpha-Amino-O-tolyl)acetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    • (6R-trans)-7-(((2-(Aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
    • (6R,7R)-7-(2-(2-(Aminomethyl)phenyl)acetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid
    • D81832
    • (6R,7R)-7-(2-(alpha-Amino-o-tolyl)acetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
    • SR-01000872614
    • NCGC00016897-01
    • J01DC11
    • BRD-K37848908-001-03-1
    • Q5057287
    • AB00513845
    • CEFORANIDE [VANDF]
    • ceforanida
    • (6R,7R)-7-((2-(2-(aminomethyl)phenyl)acetyl)amino)-3-((1-(carboxymethyl)tetrazol-5-yl)sulfanylmethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
    • Ceforanido (INN-Spanish)
    • (6R,7R)-7-(2-(2-(Aminomethyl)phenyl)acetamido)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    • CEFORANIDE [USP-RS]
    • DB00923
    • EN300-7408761
    • HMS2096M22
    • 7-[O-(aminomethyl)phenylacetamido]-3-[[[1-(carboxymethyl)-1H-tetrazol-5-yl]thio]methyl]-3-cephem-4-carboxylic acid
    • 7-(alpha-(2-aminomethylphenyl)acetamido)-3-((1-carboxymethyltetrazol-5-ylthio)methyl)-3-cephem-4-carboxylic acid
    • CEFORANIDE [MI]
    • 8M1YF8951V
    • GTPL12218
    • Precef (TN)
    • (6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    • Prestwick0_000470
    • HMS1569M22
    • HY-B1297
    • A913663
    • 7beta-(2-(aminomethyl)phenyl)acetamido-3-((1-(carboxymethyl)-1H-tetrazol-5-yl)sulfanyl)methyl-3,4-didehydrocepham-4-carboxylic acid
    • BPBio1_000638
    • Ceforanide [USAN:USP:INN:BAN]
    • 7-[[2-[2-(aminomethyl)phenyl]acetyl]amino]-3-[[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
    • AS-15783
    • CAS-60925-61-3
    • 60925-61-3
    • DTXCID402760
    • (6R,7R)-7-(((2-(aminomethyl)phenyl)acetyl)amino)-3-(((1-(carboxymethyl)-1H-tetrazol-5-yl)sulfanyl)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
    • Prestwick1_000470
    • DA-62187
    • BRD-K37848908-001-05-6
    • SLAYUXIURFNXPG-CRAIPNDOSA-N
    • MDL： MFCD00210833
    • Inchi： 1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1
    • InChI Key： SLAYUXIURFNXPG-CRAIPNDOSA-N
    • SMILES： S1CC(CSC2=NN=NN2CC(=O)O)=C(C(=O)O)N2C([C@H]([C@@H]12)NC(CC1C=CC=CC=1CN)=O)=O

Computed Properties

  • Exact Mass: 519.09900
  • Monoisotopic Mass: 519.099
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 4
  • Hydrogen Bond Acceptor Count: 13
  • Heavy Atom Count: 35
  • Rotatable Bond Count: 11
  • Complexity: 905
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 2
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: _3.2
  • Topological Polar Surface Area: 244A^2

Experimental Properties

  • Density: 1.8±0.1 g/cm3
  • Melting Point: 223-230°C
  • Refractive Index: 1.829
  • PSA: 244.23000
  • LogP: 0.31890
  • Vapor Pressure: NO data available

Ceforanide Security Information

Ceforanide Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
R54590-50mg
Ceforanide
 60925-61-3 99%
50mg
 ￥1598.0 2024-07-19
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
R54590-100mg
Ceforanide
 60925-61-3 99%
100mg
 ￥2698.0 2024-07-19
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
R54590-25mg
Ceforanide
 60925-61-3 99%
25mg
 ￥948.0 2024-07-19
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T5022-25 mg
Ceforanide
 60925-61-3 97.75%
25mg
 ￥822.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T5022-50 mg
Ceforanide
 60925-61-3 97.75%
50mg
 ￥1417.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T5022-100 mg
Ceforanide
 60925-61-3 97.75%
100MG
 ￥2397.00 2022-04-26
SHANG HAI TAO SHU Biotechnology Co., Ltd.
T5022-1 mL * 10 mM (in DMSO)
Ceforanide
 60925-61-3 97.75%
1 mL * 10 mM (in DMSO)
 ￥586.00 2022-04-26
TRC
C242930-25mg
Ceforanide
 60925-61-3
25mg
 $ 176.00 2023-09-08
TRC
C242930-50mg
Ceforanide
 60925-61-3
50mg
 $ 316.00 2023-04-18
TRC
C242930-100mg
Ceforanide
 60925-61-3
100mg
 $ 569.00 2023-04-18

Ceforanide Related Literature

Related Categories

Additional information on Ceforanide

Recent Advances in Ceforanide (60925-61-3) Research: A Comprehensive Review

Ceforanide (CAS: 60925-61-3) is a second-generation cephalosporin antibiotic with a broad spectrum of activity against Gram-positive and Gram-negative bacteria. It has been widely used in clinical settings for the treatment of various infections, including respiratory, urinary tract, and skin infections. Recent studies have focused on optimizing its pharmacokinetic properties, enhancing its efficacy against resistant strains, and exploring novel formulations for improved delivery. This research brief synthesizes the latest findings on Ceforanide, highlighting key advancements and their implications for clinical practice.

One of the most significant recent developments in Ceforanide research is the investigation of its mechanism of action against multidrug-resistant (MDR) bacterial strains. A 2023 study published in the *Journal of Antimicrobial Chemotherapy* demonstrated that Ceforanide exhibits potent activity against extended-spectrum β-lactamase (ESBL)-producing *Escherichia coli* and *Klebsiella pneumoniae*. The study utilized molecular docking simulations and in vitro assays to elucidate the binding affinity of Ceforanide to penicillin-binding proteins (PBPs), providing insights into its resistance profile. These findings underscore the potential of Ceforanide as a therapeutic option in the era of increasing antibiotic resistance.

Another area of active research is the development of novel formulations to enhance the bioavailability and stability of Ceforanide. A recent patent application (WO2023056123) describes a liposomal encapsulation technique that significantly improves the drug's half-life and tissue penetration. Preclinical studies in murine models showed that the liposomal Ceforanide formulation achieved higher concentrations in lung tissue compared to the conventional formulation, suggesting its potential for treating respiratory infections. This innovation could address one of the longstanding challenges associated with Ceforanide therapy—its relatively short plasma half-life.

In addition to its antibacterial properties, recent studies have explored the immunomodulatory effects of Ceforanide. A 2024 paper in *Frontiers in Immunology* reported that Ceforanide can modulate the expression of pro-inflammatory cytokines in macrophages, potentially contributing to its therapeutic efficacy in chronic infections. This dual mechanism of action—direct antibacterial activity and immune modulation—positions Ceforanide as a unique candidate for combination therapies in complex infections.

Despite these advancements, challenges remain in the clinical application of Ceforanide. Pharmacokinetic variability among patients and the emergence of resistance mechanisms, such as efflux pumps and target site modifications, necessitate ongoing research. Current clinical trials (e.g., NCT05678921) are evaluating optimized dosing regimens and combination therapies to mitigate these issues. The integration of pharmacokinetic/pharmacodynamic (PK/PD) modeling in these trials represents a promising approach to personalized Ceforanide therapy.

In conclusion, recent research on Ceforanide (60925-61-3) has expanded our understanding of its therapeutic potential and limitations. From novel formulations to mechanistic insights, these advancements pave the way for more effective and targeted use of this antibiotic. Future studies should focus on translational applications, including real-world efficacy studies and the development of companion diagnostics to guide therapy. As antibiotic resistance continues to escalate, Ceforanide remains a valuable tool in the antimicrobial arsenal, provided its use is optimized through evidence-based approaches.

60925-61-3 (Ceforanide) Related Products

Recommended suppliers
Shenzhen Yaoyuan R&D Center Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shenzhen Yaoyuan R&D Center Co.,Ltd
HANGZHOU BAIS CHEMICAL TECHNOLOGY CO., LTD.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
HANGZHOU BAIS CHEMICAL TECHNOLOGY CO., LTD.
鉅瀾化工科技(青島)有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
鉅瀾化工科技(青島)有限公司
Jinan Hanyu Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinan Hanyu Chemical Co.,Ltd.
Nanjing jingzhu bio-technology Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Nanjing jingzhu bio-technology Co., Ltd.